Application Value of Competing Risk Models in the Prevention of Preeclampsia

Hang GAO[1], Kai YAN[2], Ruxiu GE[1],Zhifeng MO[3,*]

1.Department of Obstetricia, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong Province, China, 518028. Email: 51325099@qq.com 2.Department of Gynaecology，Shenzhen Maternity and Child Healthcare Hospital，Shenzhen，Guangdong Province，China，518000.Email:13500051598@163.com 3,* Corresponding Author, Department of Emergency and Disaster Medical Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong Province, China, 518000 .Email: mozhf3@mail.sysu.edu.cn, https://orcid.org/0000-0002-9273-003X.

Abstract

Preeclampsia is a common complication during pregnancy that severely impacts both maternal and fetal health. In recent years, competing risk models have emerged as a novel statistical method increasingly used to investigate the risk factors and prevention strategies associated with preeclampsia. This review summarizes the current applications of competing risk models in preeclampsia research, emphasizing their value in risk assessment, preventive interventions, and clinical decision-making. Additionally, it highlights future research directions that could further enhance the understanding and management of this condition.

1 Introduction

Preeclampsia is a pregnancy-specific hypertensive disorder characterized by new-onset hypertension and proteinuria, typically occurring after the 20th week of gestation. It poses significant risks to both maternal and fetal health, including the potential for severe complications such as eclampsia, placental abruption, and fetal growth restriction. The clinical importance of preeclampsia cannot be overstated, as it affects approximately 2-8% of pregnancies globally, making it a leading cause of maternal and perinatal morbidity and mortality[1]. Early identification and management of at-risk women are crucial for improving outcomes, which has led to the development of various risk assessment strategies.

Traditional methods for assessing the risk of preeclampsia have included clinical history, physical examination, and basic laboratory tests. However, these approaches often exhibit limitations in sensitivity and specificity, leading to either false reassurance or unnecessary interventions[2]. For instance, relying solely on maternal demographics or previous pregnancy history may overlook significant biomarkers that could indicate a higher risk of developing the condition. As such, there is a pressing need for more robust and accurate risk prediction models that can effectively stratify women based on their individual risk profiles.

In recent years, the concept of competing risk models has gained traction in the medical research community. These models account for the presence of multiple potential outcomes that can occur simultaneously, which is particularly relevant in the context of preeclampsia. By incorporating competing risks, researchers can better understand the interplay between various factors that influence the development of preeclampsia and other pregnancy complications. This approach allows for a more nuanced analysis of risk factors and outcomes, ultimately leading to improved clinical decision-making and patient management[3]. The rise of competing risk models represents a significant advancement in the field of obstetrics and gynecology, offering new insights into the complexities of pregnancy-related disorders.

2 Advancements in Risk Assessment and Prevention of Preeclampsia: The Role of Competing Risk Models and Future Research Directions

2.1 Basic Principles of Competing Risk Models

Competing risks refer to situations in survival analysis where an individual can experience one of several different events, each of which precludes the occurrence of the other events. In clinical research, this is particularly relevant in scenarios involving multiple causes of failure, such as cancer studies where patients may die from cancer or from other causes, such as cardiovascular disease or secondary malignancies. The presence of competing risks complicates the interpretation of survival data, as traditional survival analysis methods, which assume that censoring is the only risk, can lead to biased estimates of survival probabilities. For instance, in a study investigating prognostic factors in patients with osteosarcoma, it was found that using a competing risks approach provided a more accurate survival prediction compared to traditional methods that did

not account for the competing nature of death from other causes[4].

Understanding competing risks is essential for clinicians and researchers to make informed decisions regarding treatment and to evaluate the effectiveness of interventions accurately. The mathematical framework for competing risks is built on survival analysis principles but incorporates the presence of multiple potential failure events. The most common approach used is the Fine-Gray model, which estimates the subdistribution hazard function for a particular type of event while accounting for the presence of other competing events. This model allows researchers to derive cumulative incidence functions, which represent the probability of a specific event occurring in the presence of competing risks over time. For example, a study on hepatocellular carcinoma risk in patients with HBV-related cirrhosis utilized a competing risk nomogram to predict outcomes, demonstrating the practical application of these mathematical concepts in clinical settings[5].

By applying these mathematical foundations, researchers can better understand the dynamics of different risks and their implications for patient management. Competing risk models are an extension of traditional survival analysis, which typically focuses on the time until the occurrence of a single event. In contrast, competing risk models acknowledge that patients may experience different events that can influence the probability of the primary event of interest. This relationship is crucial in fields such as oncology, where patients often face multiple potential outcomes.

For instance, a study on the survival probability of patients with sickle cell anemia illustrated how competing risks can provide a more nuanced understanding of patient outcomes compared to conventional survival analysis techniques[6]. By incorporating competing risks into survival analysis, researchers can derive more accurate survival estimates and better inform clinical decision-making, ultimately improving patient care and outcomes.

2.2 Risk Factors for Preeclampsia

Genetic predisposition plays a significant role in the risk of developing preeclampsia. Studies have indicated that women with a family history of preeclampsia are at a higher risk of experiencing this condition themselves, suggesting a hereditary component to its etiology. Specific genetic variants, particularly those associated with endothelial function and immune response, have been implicated in the pathophysiology of preeclampsia. For instance, polymorphisms in genes related to angiogenesis and inflammation may influence a woman's susceptibility to preeclampsia, as these processes are crucial in the development of the placenta and regulation of blood pressure during pregnancy. A cohort study highlighted that women with a history of preeclampsia in previous pregnancies are more likely to experience recurrence, reinforcing the genetic aspect of this condition[7]. Furthermore, twin studies have revealed that the heritability of preeclampsia is substantial, indicating that genetic factors contribute significantly to the risk of developing this pregnancy complication[8]. Understanding the genetic underpinnings of preeclampsia could lead to better screening and preventive strategies for at-risk populations.

Environmental factors also play a critical role in the development of preeclampsia. Various studies have identified lifestyle and environmental exposures that may increase the risk of this

condition. For instance, high levels of stress, poor nutrition, and exposure to pollutants have been linked to adverse pregnancy outcomes, including preeclampsia. Research has shown that women living in areas with high air pollution levels may have an increased risk of developing preeclampsia, possibly due to the inflammatory responses triggered by environmental toxins[9]. Additionally, socio-economic factors, such as access to healthcare and education, can influence the prevalence of preeclampsia, as disadvantaged populations may face higher risks due to inadequate prenatal care and unhealthy living conditions[10]. Furthermore, dietary factors, including high salt intake and low antioxidant consumption, have been associated with increased blood pressure and vascular dysfunction, which are critical in the pathogenesis of preeclampsia. Addressing these environmental influences is essential for reducing the incidence of preeclampsia among pregnant women.

Pregnancy-related factors significantly impact the risk of developing preeclampsia. Maternal age, parity, and the presence of multiple gestations are notable contributors. Advanced maternal age, particularly in women over 35, has been linked to a higher incidence of preeclampsia, possibly due to age-related vascular changes and an increased likelihood of pre-existing health conditions[11]. Additionally, first-time mothers (nulliparous women) are at a greater risk compared to those who have had previous pregnancies, as the immune system's adaptation to the placenta may be less developed in first pregnancies[12]. The risk is further amplified in multiple pregnancies, such as twins or triplets, due to the increased placental mass and associated hemodynamic changes[8]. Other factors, such as pre-existing hypertension, obesity, and diabetes, are also significant risk factors for preeclampsia, highlighting the multifactorial nature of this condition. Understanding these pregnancy-related factors can aid healthcare providers in identifying high-risk patients and implementing early interventions to mitigate the risks associated with preeclampsia.

2.3   Application of Competing Risk Models in Preeclampsia Risk Assessment

Competing risk models have emerged as a powerful tool in the evaluation of preeclampsia risk, offering a nuanced approach that accounts for various outcomes that may occur concurrently. These models typically involve the integration of diverse datasets encompassing maternal demographics, clinical history, and biochemical markers. Data collection often includes longitudinal studies, where pregnant women are monitored for risk factors associated with preeclampsia, such as obesity, hypertension, and family history of the condition. For instance, a study highlighted the importance of early identification of risk factors through multi-marker models, significantly enhancing prediction accuracy in high-risk populations, such as those with pregestational conditions or a history of preeclampsia in previous pregnancies[13](Figure 1).

Moreover, the feasibility of universal screening for preeclampsia risk has been investigated, emphasizing the need for standardized protocols in data collection to ensure consistency and reliability across studies[14]. By utilizing advanced statistical techniques, researchers can better understand the interplay of various risk factors and their contribution to the onset of preeclampsia, ultimately leading to improved clinical decision-making and patient outcomes.

Figure 1: Flowchart of this prospective screening study.   Legend: PE = Preeclampsia, SGA = Small-for-gestational-age, AGA = Appropriate-for-gestational-age, n = number

Recent studies employing competing risk models have yielded significant insights into the clinical management of preeclampsia. One critical finding is the identification of specific maternal risk factors that can predict the likelihood of developing early-onset preeclampsia. For example, a population-based cohort study demonstrated that certain pregestational factors, such as advanced maternal age and pre-existing hypertension, substantially increase the risk of both preterm and term preeclampsia[15]. The clinical significance of these findings underscores the necessity for tailored monitoring and intervention strategies for at-risk populations.

Furthermore, the application of these models has facilitated the development of targeted preventive measures, such as recommending low-dose aspirin for women identified at high risk. This intervention has been shown to reduce the incidence of preeclampsia[16]. This proactive approach not only enhances maternal and fetal outcomes but also optimizes healthcare resource allocation

by focusing interventions on those who would benefit the most.

When comparing competing risk models to traditional risk assessment methods, several advantages become evident. Traditional approaches often rely on binary classifications of risk, which can oversimplify the complex nature of preeclampsia and overlook the multifactorial aspects of its etiology. In contrast, competing risk models offer a more comprehensive framework that accommodates multiple potential outcomes, providing a better understanding of the dynamics at play during pregnancy. For instance, while traditional methods may focus solely on the likelihood of developing preeclampsia, competing risk models can account for other pregnancy-related complications, such as gestational diabetes or preterm birth, which may influence the overall risk profile[17].

This holistic perspective is crucial in clinical settings, where healthcare providers must navigate various risk factors and outcomes to deliver optimal care. Additionally, the predictive accuracy of competing risk models has been shown to surpass that of traditional methods, enhancing clinical decision-making and patient management strategies[18]. Ultimately, the integration of these advanced modeling techniques represents a significant advancement in the field of obstetrics, paving the way for more personalized and effective approaches to preeclampsia risk assessment.

2.4   Competing Risk Models in the Prevention of Preeclampsia

Risk stratification is a crucial component in the prevention of preeclampsia, enabling healthcare providers to identify high-risk patients and tailor interventions accordingly. Individualized interventions based on risk assessment can significantly enhance the effectiveness of preventive strategies. Recent studies have highlighted the importance of accurately identifying women at risk for preeclampsia through various factors, including medical history, genetic predispositions, and lifestyle choices.

For instance, the Gottesfeld-Hohler Memorial Foundation emphasizes the necessity of early risk assessment for early-onset preeclampsia, advocating for a proactive approach that integrates personal and familial risk factors into clinical practice[19]. Additionally, the implementation of low-dose aspirin as a preventive measure has shown promise, particularly in women identified as high-risk through stratification methods[20]. A network meta-analysis further supports the comparative effectiveness of various prophylactic strategies, underscoring the need for personalized care plans that cater to the specific risk profiles of patients[21]. This individualized approach not only improves outcomes but also fosters better patient engagement and adherence to preventive measures.

The effectiveness of preventive measures in managing preeclampsia is contingent upon their proper implementation and adherence to guidelines. Evidence suggests that systematic application of prophylactic strategies, such as the administration of low-dose aspirin and lifestyle modifications, can lead to a significant reduction in the incidence of preeclampsia among high-risk populations[22]. Furthermore, studies focusing on self-care strategies before and during pregnancy have demonstrated that empowering women with knowledge and resources can enhance the control of risk factors associated with preeclampsia[23]. The success of these interventions

is often linked to the quality of risk factor screening and the education provided to expectant mothers, which can lead to early detection and timely management of potential complications.

As healthcare systems continue to evolve, the integration of technology and telemedicine into preventive care presents new avenues for improving access and adherence to preventive measures, ultimately leading to better maternal and fetal outcomes. Optimizing clinical pathways for the prevention of preeclampsia is essential for improving care delivery and patient outcomes.

Clinical pathways that are well-structured and evidence-based can facilitate the standardization of care, ensuring that all patients receive timely and appropriate interventions based on their risk profiles. Recent advancements in technology and data analytics have enabled healthcare providers to refine these pathways, incorporating real-time data to adjust care plans as needed[11]. The use of clinical pathways not only streamlines the management of preeclampsia but also enhances interprofessional collaboration, allowing for a more cohesive approach to patient care.

Moreover, optimizing these pathways can lead to improved resource allocation and reduced healthcare costs, as demonstrated by studies focusing on quality improvement initiatives in family medicine residency training[24]. As the landscape of maternal healthcare continues to change, ongoing research and evaluation of clinical pathways will be critical in ensuring that they remain effective and responsive to the needs of patients at risk for preeclampsia.（Figure 2）

2.5　Future Research Directions

The advancement of medical research necessitates the continual improvement and innovation of existing models. Current models used in clinical and preclinical research often have limitations that hinder their applicability to real-world scenarios. For instance, the development of more sophisticated rodent models has been highlighted as a crucial step toward better mimicking human pathophysiological conditions, such as myocardial ischemia and reperfusion injury, which could lead to enhanced understanding and treatment of cardiovascular diseases[25]. Additionally, innovative outpatient models are being explored to improve patient care and streamline healthcare delivery[26].

The integration of digital technologies into these models is also essential, as it allows for real-time data collection and analysis, thereby improving the accuracy and reliability of research outcomes[27]. Future research should focus on refining these models to ensure they are representative of diverse populations and can accommodate the complexities of multifactorial diseases. This will require interdisciplinary collaboration and a commitment to adopting new technologies and methodologies that can enhance the robustness of research findings[28].

The importance of multicenter studies in medical research cannot be overstated. These studies provide a broader perspective by incorporating diverse patient populations and clinical practices, which enhances the generalizability of research findings. For example, a multicenter study on the efficacy of convalescent plasma transfusion for COVID-19 demonstrated significant variations in treatment outcomes across different centers, underscoring the necessity of multicentric approaches to understanding complex diseases[29].

Additionally, multicenter studies facilitate the pooling of resources and data, leading to more

Figure 2: ROC curves with prediction model of prior and posterior risks for early and late PE. Legend: (a) (······) Prior Risk for early PE, (——) Posterior Risk for early PE; (b) (– · – · – ·) Prior Risk for late PE, (——) Posterior Risk for late PE

comprehensive analyses and stronger statistical power. The variation in treatment protocols and patient demographics across centers can provide valuable insights into the effectiveness of various interventions[30]. As healthcare becomes increasingly globalized, future research should prioritize multicenter collaborations to address the heterogeneity of patient responses and treatment efficacy, ultimately leading to more tailored and effective healthcare solutions[31].

The emergence of big data has transformed the landscape of medical research, offering unprecedented opportunities for data sharing and analysis. The integration of large datasets can significantly enhance our understanding of disease mechanisms and patient outcomes. For in-

stance, utilizing shared big data has proven effective in identifying liver cancer dedifferentiation markers, which could lead to more targeted therapies[32].

Moreover, the challenges of big data integration in life sciences highlight the need for robust data governance and standardized data models to facilitate effective data sharing[33]. As researchers increasingly recognize the human aspect of big data, it is crucial to develop frameworks that ensure ethical data-sharing practices while maximizing the potential benefits of these vast datasets[34]. Future research should focus on creating collaborative platforms that promote data sharing among institutions, enabling researchers to leverage collective insights and drive innovation in patient care and treatment strategies[35].

3   Conclusion

In conclusion, the development and application of competing risk models represent a significant advancement in the risk assessment and prevention strategies for preeclampsia. These models provide a nuanced perspective, allowing clinicians to consider not only the likelihood of developing preeclampsia but also the potential competing events that may influence the outcome. This multifaceted approach is crucial in tailoring individual patient care and enhancing the scientific basis of clinical decisions.

The integration of competing risk models into clinical practice has the potential to refine risk stratification processes for expectant mothers, thereby improving the identification of those at higher risk for adverse outcomes associated with preeclampsia. By acknowledging the complexities inherent in patient management, these models facilitate more informed dialogues between healthcare providers and patients, ultimately leading to better health outcomes.

However, it is essential to recognize the disparities in research methodologies and findings related to competing risk models. A balanced interpretation of the literature is necessary, as variations in study design, population demographics, and statistical approaches can yield differing results. Future research should focus on standardizing methodologies to enable clearer comparisons and validations of competing risk models across diverse populations.

Moreover, further exploration of the clinical applicability of these models within preeclampsia research is needed. Efforts should be made to encourage collaboration between researchers and clinicians to ensure that the insights gained from these models translate into actionable clinical guidelines. By fostering an environment of interdisciplinary research, we can advance our understanding of preeclampsia and ultimately improve maternal and fetal health outcomes.

In summary, while competing risk models offer promising avenues for improving preeclampsia risk assessment and management, ongoing research and collaboration are vital to harness their full potential. By addressing current gaps and promoting the integration of these models into routine clinical practice, we can pave the way for more effective prevention strategies in the field of obstetrics.

References

[1] Bouter AR, Duvekot JJ. Evaluation of the clinical impact of the revised ISSHP and ACOG definitions on preeclampsia. Pregnancy Hypertens. 2020;19:206-211. doi:10.1016/j.preghy.2019.11.011

[2] Stekkinger E, Scholten RR, Heidema WM, Spaanderman MEA. Comparison of three definitions of metabolic syndrome and relation to risk of recurrent preeclampsia. Hypertens Pregnancy. 2021;40(1):97-108. doi:10.1080/10641955.2021.1872614

[3] Austin PC, Ibrahim M, Putter H. Accounting for Competing Risks in Clinical Research. JAMA. 2024;331(24):2125-2126. doi:10.1001/jama.2024.4970

[4] Wu X, Wang J, He D. Establishment and validation of a competitive risk model for predicting cancer-specific survival in patients with osteosarcoma: a population-based study. J Cancer Res Clin Oncol. 2023;149(17):15383-15394. doi:10.1007/s00432-023-05320-x

[5] Guo D, Li J, Zhao P, Mei T, Li K, Zhang Y. The hepatocellular carcinoma risk in patients with HBV-related cirrhosis: a competing risk nomogram based on a 4-year retrospective cohort study. Front Oncol. 2024;14:1398968. Published 2024 May 16. doi:10.3389/fonc.2024.1398968

[6] do Nascimento EM, de Castro Lobo CL, de Bragança Pereira B, Ballas SK. Survival Probability in Patients with Sickle Cell Anemia Using the Competitive Risk Statistical Model. Mediterr J Hematol Infect Dis. 2019;11(1):e2019022. Published 2019 Mar 1. doi:10.4084/MJHID.2019.022

[7] Ogunwole SM, Mwinnyaa G, Wang X, Hong X, Henderson J, Bennett WL. Preeclampsia Across Pregnancies and Associated Risk Factors: Findings From a High-Risk US Birth Cohort. J Am Heart Assoc. 2021;10(17):e019612. doi:10.1161/JAHA.120.019612

[8] Chantanahom N, Phupong V. Clinical risk factors for preeclampsia in twin pregnancies. PLoS One. 2021;16(4):e0249555. Published 2021 Apr 15. doi:10.1371/journal.pone.0249555

[9] Sakali AK, Papagianni M, Bargiota A, Rasic-Markovic A, Macut D, Mastorakos G. Environmental factors affecting pregnancy outcomes. Endocrine. 2023;80(3):459-469. doi:10.1007/s12020-023-03307-9

[10] Anto EO, Boadu WIO, Ansah E, et al. Prevalence of preeclampsia and algorithm of adverse foeto-maternal risk factors among pregnant women in the Central Region of Ghana: A multicentre prospective cross-sectional study. PLoS One. 2023;18(6):e0288079. Published 2023 Jun 29. doi:10.1371/journal.pone.0288079

[11] Francisco C, Gamito M, Reddy M, Rolnik DL. Screening for preeclampsia in twin pregnancies. Best Pract Res Clin Obstet Gynaecol. 2022;84:55-65. doi:10.1016/j.bpobgyn.2022.03.008

[12] Muldoon KA, McLean C, El-Chaár D, et al. Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. J Matern Fetal Neonatal Med. 2023;36(1):2200879. doi:10.1080/14767058.2023.

2200879

[13] Zhang J, Han L, Li W, et al. Early prediction of preeclampsia and small-for-gestational-age via multi-marker model in Chinese pregnancies: a prospective screening study. BMC Pregnancy Childbirth. 2019;19(1):304. Published 2019 Aug 19. doi:10.1186/s12884-019-2455-8

[14] Pimentel VM, Larrea ADA, Renaud SJ, et al. Feasibility of Universal Screening for Preeclampsia Risk and Aspirin Recommendation in the Ultrasound Unit. Am J Perinatol. 2024;41(S 01):e3187-e3195. doi:10.1055/s-0043-1777445

[15] Sande AK, Dalen I, Torkildsen EA, Sande RK, Morken NH. Pregestational maternal risk factors for preterm and term preeclampsia: A population-based cohort study. Acta Obstet Gynecol Scand. 2023;102(11):1549-1557. doi:10.1111/aogs.14642

[16] Martinez-King LC, Machiorlatti M, Ogburn T, Salcedo J. Physician's Knowledge and Practices Surrounding Low-Dose Aspirin for Preeclampsia Risk Reduction. Am J Perinatol. 2024;41(S01):e1120-e1125.doi:10.1055/a-1990-2728

[17] Kenny LC, Thomas G, Poston L, et al. Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test. PLoS One. 2020;15(12):e0244369. Published 2020 Dec 28. doi:10.1371/journal.pone.0244369

[18] Carter S, Lin JC, Chow T, et al. Preeclampsia Onset, Days to Delivery, and Autism Spectrum Disorders in Offspring: Clinical Birth Cohort Study. JMIR Public Health Surveill. 2024;10:e47396. Published 2024 Apr 17. doi:10.2196/47396

[19] Copel JA, Platt LD, Hobbins JC, et al. Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Obstet Gynecol. 2020;135(1):36-45. doi:10.1097/AOG.0000000000003582

[20] Kim SH. Reframing prediabetes: A call for better risk stratification and intervention. J Intern Med. 2024;295(6):735-747. doi:10.1111/joim.13786 https://pubmed.ncbi.nlm.nih.gov/38606904

[21] Liu YH, Zhang YS, Chen JY, et al. Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2023;228(5):535-546. doi:10.1016/j.ajog.2022.10.014

[22] Ilizaliturri AO, Jimenez K, Trejo R, Serpas S. A Quality Improvement Project in Family Medicine Residency Training: Improving Preeclampsia Prevention Through Risk Factor Screening and Low-Dose Aspirin. Am J Public Health. 2024;114(S4):S318-S321. doi:10.2105/AJPH.2024.307667

[23] Rasouli M, Pourheidari M, Hamzeh Gardesh Z. Effect of Self-care Before and During Pregnancy to Prevention and Control Preeclampsia in High-risk Women. Int J Prev Med. 2019;10:21. Published 2019 Feb 12. doi:10.4103/ijpvm.IJPVM_300_17

[24] Magee LA, Wright D, Syngelaki A, et al. Preeclampsia Prevention by Timed Birth at Term. Hypertension. 2023;80(5):969-978. doi:10.1161/HYPERTENSIONAHA.122.20565

[25] Erratum: Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury. J Vis Exp. 2022;(185):10.3791/6507. Published 2022 Jul 27. doi:10.3791/6507

[26] Köhler S, Roth-Sackenheim C, Navarro Ureña A, Mönter N. Innovative ambulante Modelle [Innovative outpatient models]. Nervenarzt. 2020;91(11):1003-1016. doi:10.1007/s00115-020-01010-y

[27] Tsai WY, Su CJ. Digital transformation of business model innovation. Front Psychol. 2022;13:1017750. Published 2022 Oct 26. doi:10.3389/fpsyg.2022.1017750

[28] Rawl SM. Future directions for research and education. Nurs Outlook. 2022;70(1):204-205. doi:10.1016/j.outlook.2021.12.004

[29] Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, et al. Convalescent Plasma Transfusion for the Treatment of COVID-19-Experience from Poland: A Multicenter Study. J Clin Med. 2020;10(1):28. Published 2020 Dec 24. doi:10.3390/jcm10010028

[30] Buda N, Cylwik J, Mróz K, et al. Lung Ultrasound Examination in Patients with SARS-CoV-2 Infection: Multicenter Study. J Clin Med. 2021;10(15):3255. Published 2021 Jul 23. doi:10.3390/jcm10153255

[31] Liu T, Wu J, Na P, et al. Necessity for higher teicoplanin doses in older adults: a multicenter prospective observational study in China. BMC Geriatr. 2024;24(1):487. Published 2024 Jun 4. doi:10.1186/s12877-024-05091-1

[32] Borziak K, Finkelstein J. Utilizing Shared Big Data to Identify Liver Cancer Dedifferentiation Markers. Stud Health Technol Inform. 2022;289:73-76. doi:10.3233/SHTI210862

[33] Fillinger S, de la Garza L, Peltzer A, Kohlbacher O, Nahnsen S. Challenges of big data integration in the life sciences. Anal Bioanal Chem. 2019;411(26):6791-6800. doi:10.1007/s00216-019-02074-9 https://pubmed.ncbi.nlm.nih.gov/31463515/

[34] Helzlsouer K, Meerzaman D, Taplin S, Dunn BK. Humanizing Big Data: Recognizing the Human Aspect of Big Data. Front Oncol. 2020;10:186. Published 2020 Mar 13. doi:10.3389/fonc.2020.00186

[35] Sui Y, Zhao J. Optimization Simulation of Supply-Side Structure of Agricultural Economy Based on Big Data Analysis in Data Sharing Environment [retracted in: J Environ Public Health. 2023 Sep 14;2023:9859873. doi: 10.1155/2023/9859873]. J Environ Public Health. 2022;2022:1497357. Published 2022 Sep 9. doi:10.1155/2022/1497357